AZD-1390 is under clinical development by AstraZeneca and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I drugs for Leiomyosarcoma have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AZD-1390’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AZD-1390 is under development for the treatment of glioblastoma multiforme (GBM), soft tissue sarcoma, liposarcoma, leiomyosarcoma and fibrosarcoma as a first line therapy. The drug candidate is administered via oral and intravenous bolus injection. It acts by targeting serine protein kinase ATM (ataxia telangiectasia mutated). It is a new molecular entity.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of AZD-1390’s drug-specific PTSR and LoA scores, buy the report here.